Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 2/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30376402 | 1.00 | GNAI3 (0.42) | GNAI3GNAO1GNAI1ALDH1A1ATM | |
| SCHEMBL13610202 | 0.94 | GNAI3 (0.47) | GNAI3GNAO1GNAI1TSHREPHX2 | |
| SCHEMBL11848695 | 0.94 | GNAI3 (0.47) | GNAI3GNAO1GNAI1TSHREPHX2 | |
| SCHEMBL6050362 | 0.90 | SLC6A1 (0.47) | ALDH1A1ATMHPGDTSHREPHX2 | |
| SCHEMBL4917731 | 0.90 | GNAI3 (0.47) | GNAI3GNAO1GNAI1ALDH1A1ATM | |
| SCHEMBL6063290 | 0.90 | PPM1B (0.41) | GNAI3GNAO1GNAI1ATMTSHR | |
| Bromide SCHEMBL11562531 | 0.88 | GNAI3 (0.46) | GNAI3GNAO1GNAI1ALDH1A1ATM | |
| SCHEMBL25299469 | 0.86 | ALDH1A1 (0.47) | ALDH1A1ATMHPGDTSHRNAAA | |
| SCHEMBL13610195 | 0.84 | TSHR (0.45) | GNAI3GNAO1GNAI1ATMTSHR | |
| SCHEMBL31221629 | 0.84 | TSHR (0.45) | GNAI3GNAO1GNAI1ATMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396565-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-12-15 | — | — | US | disclosed |
| EP-2205558-B1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF AS HISTAMINE H3 RECEPTOR MODULATORS | SANOFI SA (FR) | 2012-07-25 | — | — | EP | disclosed |
| US-8227504-B2 | Substituted N-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof | SANOFI (FR) | 2012-07-24 | — | — | US | disclosed |
| EP-2205558-A1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF AS HISTAMINE H3 RECEPTOR MODULATORS | Sanofi-Aventis (FR) | 2010-07-14 | — | — | EP | disclosed |
| US-20100173898-A1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | disclosed |
| US-20100173898-A1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | disclosed |
| WO-2009052063-A1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF AS HISTAMINE H3 RECEPTOR MODULATORS | SANOFI-AVENTIS (FR) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173898-A1 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF | HRH3, HRH4, CNR1 | GNAI3 1027/4885GNAO1 784/4885GNAI1 864/4885 |
| US-20220396565-A1 | NOVEL HETEROCYCLIC COMPOUNDS | MRPL21, F12, MRPS34 | GNAI3 2322/4885GNAO1 979/4885GNAI1 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.